R&D

Feb 25, 2013
Kenneth Getz of the Tufts Center for the Study of Drug Development looks at leveraging pharmacists as a channel to raise clinical research literacy among patient communities.
Sep 01, 2012
There is much talk today about "open innovation" in business and research forums—but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector? Does it signal a change in the way pharmaceutical companies approach research and innovation?
Jun 01, 2012
As brands are required to produce more and more data to convince not only regulators, but payers, physicians, and patients, Jeffrey Jonas is pushing Shire's "search and develop" R&D model into new and sometimes uncomfortable territory.
May 01, 2012
By Pharmaceutical Executive
Companies know they need regulatory information management. What they don't always know is where to start and how to weave this vital capability across the enterprise.
Nov 01, 2011
By Pharmaceutical Executive
Industry critics point to a lag in NME approvals as proof of innovation stagnation, but combination products and new delivery systems are quietly saving lives, and bringing in big dollars.
Sep 01, 2011
Observational studies present a compelling real-world corollary to the classic randomized clinical trial.
Sep 01, 2011
By Pharmaceutical Executive
Richard Barker, former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.
Sep 01, 2011
Industry and regulators alike must graple with the sensitivities associated with developing biosimilar drugs.
Sep 01, 2011
Pharm Exec talks to Dr. Mel Spigelman, President and CEO of the TB Alliance, about the organization's tuberculosis priorities.
Jul 01, 2011
Pfizer's crizotinib development program combined organization, art, and science—and a large dose of unforeseen risk